Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
BioNTech raised to buy at Jefferies on new cancer drug
BioNTech (NASDAQ:BNTX) shares traded higher on Tuesday after Jefferies upgraded the German COVID-19 vaccine maker to Buy from Hold, citing the potential of a new cancer drug it is developing with its Chinese partner Biotheus.
Jefferies Upgrades BioNTech SE - Depositary Receipt () (BNTX)
Fintel reports that on September 17, 2024, Jefferies upgraded their outlook for BioNTech SE - Depositary Receipt () (NasdaqGS:BNTX) from Hold to Buy. Analyst Price Forecast Suggests 8.06% Downside As of August 25,
Jefferies upgrades BioNTech SE (BNTX) to a Buy
Jefferies analyst Akash Tewari upgraded BioNTech SE (BNTX – Research Report) to a Buy today and set a price target of $150.00. The
1d
on MSN
9 Highest Dividend-Paying Stocks in the S&P 500
Ford is one of the many stocks on this list of the best dividend stocks in the S&P 500 that have seen shares slump lately.
1d
BioNTech SE ADR rises Tuesday, outperforms market
The BioNTech SE ADR BNTX rallied 1.00% to $124.71 Tuesday, on what proved to be an all-around mixed trading session for the ...
1d
ESMO 2024 Roundup: A Lot Of Stumbles, But There Are New Signs Of Life
The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...
23h
UBS Keeps Their Hold Rating on BioNTech SE (BNTX)
UBS analyst Eliana Merle maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of $131.00. The ...
21h
BioNTech SE ADR falls Wednesday, underperforms market
The BioNTech SE ADR BNTX slipped 7.29% to $115.62 Wednesday, on what proved to be an all-around rough trading session for the ...
8d
BioNTech's Low Valuation, Many Shots On Goal Make It A Buy
BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab. Find out why BNTX stock is a Buy.
Zacks.com on MSN
6d
BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar?
BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
2d
Decoding BioNTech's Options Activity: What's the Big Picture?
Today, Benzinga 's options scanner spotted 26 uncommon options trades for BioNTech. This isn't normal. The overall sentiment ...
2d
BioNTech SE: A Strong Buy on BNT327’s Promising Cancer Treatment Prospects and Financial Fortitude
In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
BioNTech SE
Dow Jones Industrial Average
Trade
Jefferies
Merck & Co.
Feedback